Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study

Gynecologic Oncology

Volumn 132, Issue 3, 2014, Pages 585-592

  Fleming, Gini F ^a   Filiaci, Virginia L ^b   Marzullo, Brandon ^b   Zaino, Richard J ^c   Davidson, Susan A ^d   Pearl, Michael ^e   Makker, Vicky ^f   Burke II, James J ^g   Zweizig, Susan L ^h   Van Le, Linda ⁱ   Hanjani, Parviz ^j   Downey, Gordon ^k   Walker, Joan L ^l   Reyes, Henry D ^m   Leslie, Kimberly K ^m  

^a UNIVERSITY OF CHICAGO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^e STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

^h UMASS MEMORIAL MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j Hanjani Institute for Gynecologic Oncology   (United States)

^k Gynecologic Oncology of West Michigan   (United States)

^l UNIVERSITY OF OKLAHOMA   (United States)

^m UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

more..

Author keywords

Endometrial cancer; Hormonal therapy; Megestrol acetate; Tamoxifen; Temsirolimus

Indexed keywords

MEGESTROL ACETATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TAMOXIFEN; TEMSIROLIMUS;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; EDEMA; ENDOMETRIUM CARCINOMA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MIDDLE AGED; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH; TREATMENT RESPONSE; VERY ELDERLY;

ENDOMETRIAL CANCER; HORMONAL THERAPY; MEGESTROL ACETATE; TAMOXIFEN; TEMSIROLIMUS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MEGESTROL ACETATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SIROLIMUS; TAMOXIFEN;

EID: 84896393304     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.01.015     Document Type: Article

References (35)

1. J.T. Thigpen, M.F. Brady, R.D. Alvarez, M.D. Adelson, H.D. Homesley, and A. Manetta et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group J Clin Oncol 17 1999 1736 1744
2. J.V. Fiorica, V.L. Brunetto, P. Hanjani, S.S. Lentz, R. Mannel, and W. Andersen Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 92 2004 10 14
3. M. Singh, R.J. Zaino, V.J. Filiaci, and K.K. Leslie Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study Gynecol Oncol 106 2007 325 333
4. G.F. Fleming, V.L. Brunetto, D. Cella, K.Y. Look, G.C. Reid, and A.R. Munkarah et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study J Clin Oncol 22 2004 2159 2166
5. B. Weigelt, and S. Banerjee Molecular targets and targeted therapeutics in endometrial cancer Curr Opin Oncol 24 2012 554
6. I. Diaz-Padilla, I. Duran, B.A. Clarke, and A.M. Oza Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer Cancer Treat Rev 38 2012 767 775
7. C. Gu, Z. Zhang, Y. Yu, Liu, F. Zhao, and L. Yin et al. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer Cancer Sci 102 2011 557 564
8. A. Pant, I.I. Lee, Z. Lu, B.R. Rueda, J. Schink, and J.J. Kim Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin PLoS One 7 2012 e41593
9. J. Baselga, M. Campone, M. Piccart, H.A. Burris 3rd, H.S. Rugo, and T. Sahmoud et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 2012 520 529
10. W.B. London, and M.N. Chang One- and two-stage designs for stratified phase II clinical trials Stat Med 24 2005 2597 2611
11. E.N. Atkinson, and B.W. Brown Confidence limits for probability of response in multistage phase II clinical trials Biometrics 41 1985 741 744
12. W.J. Conover Practical Nonparametric Statistics III ed. 1998 John Wiley & Sons New York
13. W. Pirie Jonckheere Tests for Ordered Alternatives S. Kotz, N.L. Johnson, Encyclopedia of Statistical Sciences vol. 4 1983 John Wiley & Sons New York 315 318
14. A. Agresti A survey of exact inference for contingency tables Stat Sci 7 1992 131 153
15. D.R. Cox Regression Models and Life Tables J R Stat Soc Ser B 20 1972 [187-20]
16. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
17. A.M. Oza, L. Elit, M.S. Tsao, S. Kamel-Reid, J. Biagi, and D.M. Provencher et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J Clin Oncol 29 2011 3278 3285
18. S. Nagao, S. Nishio, H. Michimae, H. Tanabe, S. Okada, and T. Otsuki et al. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study Gynecol Oncol 131 2013 567 573
19. B.M. Slomovitz, K.H. Lu, T. Johnston, R.L. Coleman, M. Munsell, and R.R. Broaddus et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer 116 2010 5415 5419
20. B. Slomovitz et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma: Can pahtologic factors predicct response? ESGO 2011 (Abstract 1758)
21. B.B. Ma, A. Oza, E. Eisenhauer, G. Stanimir, M. Carey, and W. Chapman et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers-a study of the National Cancer Institute of Canada Clinical Trials Group Int J Gynecol Cancer 14 2004 650 658
22. T. Bachelot, C. Bourgier, C. Cropet, I. Ray-Coquard, J.M. Ferrero, and G. Freyer et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study J Clin Oncol 30 2012 2718 2724
23. G.S. Bhattacharyya, J. Biswas, J.K. Singh, M. Singh, K. Govindbabu, and A.A. Ranade et al. Reversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breast cancer Eur J Cancer 47 2011 9
24. C.L. Loprinzi, J.W. Kugler, J.A. Sloan, J.A. Mailliard, J.E. Krook, and M.B. Wilwerding et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia J Clin Oncol 17 1999 3299 3306
25. S. Huber, C.J. Bruns, G. Schmid, P.C. Hermann, C. Conrad, and H. Niess et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis Kidney Int 71 2007 771 777
26. K. Sekizawa, T. Matsui, T. Nakagawa, K. Nakayama, and H. Sasaki ACE inhibitors and pneumonia Lancet 352 1998 1069
27. J. Kharofa, E.P. Cohen, R. Tomic, Q. Xiang, and E. Gore Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy Int J Radiat Oncol Biol Phys 84 2012 238 243
28. B. Djordjevic, B.T. Hennessy, J. Li, B.A. Barkoh, R. Luthra, and G.B. Mills et al. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing Mod Pathol 25 2012 699 708
29. A.M. Oza, A. Poveda, A.R. Clamp, S. Pignata, G. Scambia, and J.M. Del Campo et al. A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotherapy (C) in female adult patients with advanced endometrial carcinoma J Clin Oncol 29 2011 [ASCO 5009 (abstr)]
30. O. Tredan, I. Treilleux, Q. Wang, N. Gane, D. Pissaloux, and N. Bonnin et al. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study Target Oncol 8 2013 243 251
31. S. Yang, X. Xiao, X. Meng, and K.K. Leslie A mechanism for synergy with combined mTOR and PI3 kinase inhibitors PLoS One 6 2011 e26343
32. A.P. Myers New strategies in endometrial cancer: Targeting the PI3K/mTOR pathway - - The devil is in the details Clin Cancer Res 19 2013 5264 5274
33. I. Ray-Coquard, L. Favier, and B. Weber et al. Everolimus as second-or third line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO Br J Cancer 108 2013 1771 1777
34. N. Colombo, D.S. McMeekin, P.E. Schwartz, C. Sessa, P.A. Gehrig, and R. Holloway et al. Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm phase 2 trial Br J Cancer 108 2013 1021 1026
35. H. Mackay, S. Welch, M.S. Tsao, J.J. Biagi, L. Elit, and P. Ghatage et al. A phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192 J Clin Oncol 29 2011 [ASCO 5013 (abstr)]